Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 38.00 INR
Change Today +1.00 / 2.70%
Volume 37.4K
ICP On Other Exchanges
Symbol
Exchange
ICP is not on other exchanges.
As of 6:06 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

iol chemicals and pharma ltd (ICP) Snapshot

Open
38.00
Previous Close
37.00
Day High
39.55
Day Low
36.00
52 Week High
11/21/14 - 77.10
52 Week Low
04/1/14 - 19.00
Market Cap
1.8B
Average Volume 10 Days
42.5K
EPS TTM
1.21
Shares Outstanding
47.7M
EX-Date
02/28/97
P/E TM
31.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for IOL CHEMICALS AND PHARMA LTD (ICP)

Related News

No related news articles were found.

iol chemicals and pharma ltd (ICP) Related Businessweek News

No Related Businessweek News Found

iol chemicals and pharma ltd (ICP) Details

IOL Chemicals and Pharmaceuticals Limited manufactures and sells industrial organic chemicals and bulk drugs worldwide. It operates through Chemicals and Drugs segments. The Chemicals segment offers ethyl acetate, acetic anhydride, acetyl chloride, mono chloro acetic acid, and Iso butyl benzene chemical products for use in flexible packaging, pharmaceuticals, textiles, food processing, pesticides, and paint industries. The Drugs segment provides various active pharmaceutical ingredients, such as ibuprofen, ibuprofen sodium, dex-ibuprofen, omeprazole, lansoprazole, metformin hydrochloride, lamotrigine, fenofibrate, losartan potassium, desloratadine, fluconazole, clopidogrel bi sulphate, tramadol hydrochloride, telmisartan, olmesartan, hydrochlorothiazide, rosuvastatin calcium, oxcarbazepine, and olanzapine for use in various therapeutic categories, including pain management, anti-diabetic, anti-hypertensive, anti-convulsants, anti-ulcer, anti-cholesterol, anti-histaminic, anti-fungal, anti-platlet, analgesic, and diuretic. The company was founded in 1986 and is headquartered in Ludhiana, India.

1,075 Employees
Last Reported Date: 09/3/14
Founded in 1986

iol chemicals and pharma ltd (ICP) Top Compensated Officers

Managing Director, Director and Member of Sta...
Total Annual Compensation: 1.9M
Joint Managing Director and Whole Time Direct...
Total Annual Compensation: 1.7M
Director of Works, Director and Member of Sta...
Total Annual Compensation: 1.4M
Compensation as of Fiscal Year 2014.

iol chemicals and pharma ltd (ICP) Key Developments

IOL Chemicals and Pharmaceuticals Ltd. Reports Standalone Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

IOL Chemicals and Pharmaceuticals Ltd. reported standalone unaudited earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported total income from operations (net) of INR 679.583 million compared to INR 1,390.981 million a year ago. Loss from operations before other income, interest and exceptional items was INR 180.345 million compared to profit from operations before other income, interest and exceptional items of INR 158.869 million a year ago. Loss from ordinary activities before tax was INR 320.955 million compared to profit from ordinary activities before tax of INR 13.254 million a year ago. Net loss for the period was INR 300.938 million or INR 7.58 per diluted share before and after extraordinary items compared to net profit for the period of INR 5.894 million or INR 0.21 per basic and diluted share before and after extraordinary items a year ago. For the nine months, the company reported total income from operations (net) of 3,107.507 million compared to INR 4,338.023 million a year ago. Loss from operations before other income, interest and exceptional items was INR 1.567 million compared to profit from operations before other income, interest and exceptional items of INR 494.428 million a year ago. Loss from ordinary activities before tax was INR 445.011 million compared to profit from ordinary activities before tax of INR 41.044 million a year ago. Net loss for the period was INR 385.952 million or INR 9.66 per diluted share before and after extraordinary items compared to net profit for the period of INR 24.891 million or INR 0.93 per basic and diluted share before and after extraordinary items a year ago.

IOL Chemicals and Pharmaceuticals Ltd. to Report Q3, 2015 Results on Feb 13, 2015

IOL Chemicals and Pharmaceuticals Ltd. announced that they will report Q3, 2015 results on Feb 13, 2015

IOL Chemicals and Pharmaceuticals Ltd., Board Meeting, Feb 13, 2015

IOL Chemicals and Pharmaceuticals Ltd., Board Meeting, Feb 13, 2015. Agenda: To consider and approve the un-audited financial results of the company for the quarter ended December 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICP:IN 38.00 INR 0.00

ICP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ICP.
View Industry Companies
 

Industry Analysis

ICP

Industry Average

Valuation ICP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.3x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IOL CHEMICALS AND PHARMA LTD, please visit www.iolcp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.